Available Online: 26 Jan 2026
Volume 2
Vladimir N. Pak
oncoshut@gmail.com
Available Online: 23 Dec 2025
Volume 1
Abinash Nayak
abinashnayakzoology@gmail.com
The BCL2 family of proteins serves as a central regulator of mitochondrial outer membrane permeabilization (MOMP) and intrinsic apoptosis, with anti-apoptotic members such as BCL2, BCL-XL, and MCL1 frequently overexpressed in cancers to evade programmed cell death. Traditional BH3 mimetics, like venetoclax and navitoclax, have revolutionized treatment for hematologic malignancies by competitively inhibiting these pro-survival proteins, yet they face challenges including acquired resistance, on-target toxicities and limited efficacy in solid..
Published: 17 Jun 2025
Volume 1
Walaa K. Mousa
walaa.mousa@aau.ac.ae
Aya Al Ali
202221536@aau.ac.ae
Ranim W. A. Abdelmoteleb
ranim.abdelmoteleb@aau.ac.ae
Ruqaia Al Shami
ruqaia.alshami@aau.ac.ae
Najwa Al Ramadan
201920320@aau.ac.ae
Sedq Moutraji
sedq.moutraji@aau.ac.ae
Rose Ghemrawi
rose.ghemrawi@aau.ac.ae
Published: 23 May 2025
Volume 1
Bilal Rah
BRah@sharjah.ac.ae
Menattullah W. Mohamed
U24103098@sharjah.ac.ae
Aisha S. Janeeh
U21103311@sharjah.ac.ae
Tayma M. Kurabi
U24103495@sharjah.ac.ae
Jasmin S. Abdul Salam
jsalam@sharjah.ac.ae
Mawieh Hamad
mabdelhaq@sharjah.ac.ae
Published: 15 Apr 2025
Volume 1
Abdo Meyiah
Abdo.Meyiah@xjtlu.edu.cn
Mohammad A. Al-Mterin
mhm8160506@ju.edu.jo
Khaled Murshed
kmurshed@hamad.qa
Eyad Elkord
eyad.elkord@xjtlu.edu.cn
Published: 21 Mar 2025
Volume 1
Darya Nizheharodava
nzh@tut.by
Elizaveta Nazaranka
el.m.nazarenko@gmail.com
Natallia Marozava
natalim-22@yandex.ru
Galina Ivanchyk
immunology.by@gmail.com
Volha Karnialiuk
olsol70@mail.ru
Zhanna Kaliadzich
janept@list.ru
Marina Zafranskaya
zafranskaya@gmail.com
Introduction. Tumor infiltrating lymphocytes are a major component of sinonasal neoplasms, actively populating tumor tissue, yet their role remains poorly understood. The aim is to characterize subsets and functional profiles of tumor infiltrating lymphocytes in patients with benign and malignant sinonasal tumors. Materials and methods. Tumor infiltrating lymphocytes were isolated from the biopsy material of 58 patients: 18 with sinonasal malignancies, 23 with inverted papilloma and 17 with polypous rhinosinusitis..
Published: 19 Mar 2025
Volume 1
Fathima Hasnain Nadeem Hussain
fathima279h@gmail.com
Khadija Shafique
700045914@uaeu.ac.ae
Afsheen Raza
raza.afsheen@adu.ac.ae
Lung cancer is the major cause of mortality worldwide with non-small cell lung cancer (NSCLC) contributing to 85% of the cases. FDA-approved immune checkpoint inhibitors (ICI), anti-PD-1, and anti-PD-L1 are widely used as a standard treatment. However, the response rate is limited and is observed in only 20–40% of the patients. Therefore, predictive and prognostic biomarkers are needed to help differentiate responders from non-responders, enabling a better understanding of disease..
Published: 11 Feb 2025
Volume 1
Fakhra Alafeefi
Fakhraalafifi@gmail.com
Afsheen Raza
raza.afsheen@adu.ac.ae
This review explores the progression of CRISPR-Cas9 genome editing technology in gene therapy for acute myeloid leukemia. Acute Myeloid Leukemia, a serious blood cancer, presents formidable treatment obstacles and a dismal prognosis. Effective treatments for acute myeloid leukemia rely on a clear understanding of its intricate genetic mechanisms, and CRISPR-Cas9 technology offers precision and adaptability for targeting the disease’s oncogenic drivers. The dual intron-targeting method of CRISPR-Cas9 is showcased in..
Published: 08 Jan 2025
Volume 1
Fakhra Alafeefi
Fakhraalafifi@gmail.com
Afsheen Raza
raza.afsheen@adu.ac.ae
Relapse of Chronic Myelomonocytic Leukemia after allogeneic hematopoietic stem cell transplantation remains a significant challenge, with relapse rates reaching up to 50%, contributing to poor survival outcomes. This paper explores the factors influencing relapse, including disease biology and persistence of residual disease. Current, post- transplant strategies, such as maintenance therapies and immunomodulatory treatments, are discussed for their potential to reduce the likelihood of relapse. It also highlights emerging therapies, such..
Published: 21 Oct 2024
Volume 1
Saad Ahmed
saad0ahmed18@gmail.com
Muhammad Shayaan Mazhar
shayaanmazhar7@gmail.com
Muhammad Fahad Shabbir
fahadshabbir166@gmail.com
Published: 16 Jan 2026
Volume 1
It is my honor as Editor-in-Chief to present the first volume of Targeted Cancer Therapy Connect, a new peer-reviewed journal dedicated to the rapidly advancing field of targeted cancer therapeutics. The aim of this first volume and of subsequent publications is to deepen our understanding of the molecular and cellular drivers of cancer and to highlight strategies that selectively target these molecules or pathways to improve therapeutic efficacy and patient..